Cancer cells use the interaction between immune-checkpoint receptor programmed cell death protein 1 (PD-1) on activated T cells and programmed cell death ligand 1 (PD-L1) on tumor cells and various cell types of the tumor microenvironment to evade immune surveillance. Blocking the interaction between PD-1 and PD-L1 with checkpoint inhibitors can improve T-cell reactions and mediate efficient antitumor activity in a variety of solid tumors including melanoma. However, clinical data from patients with myeloid diseases that are treated with these agents are limited to clinical trials in advanced disease. Pembrolizumab (PEM) is a humanized monoclonal antibody of the immunoglobulin G4/κ isotype designed to block PD-1/PD-L1 interactions and is approved for various solid tumors including advanced melanoma.
| Identifer | oai:union.ndltd.org:DRESDEN/oai:qucosa:de:qucosa:34908 |
| Date | 09 August 2019 |
| Creators | Kubasch, Anne Sophie, Wehner, Rebekka, Bazzurri, Serena, Tunger, Antje, Stasik, Sebastian, Garzarolli, Marlene, Meinel, Jörn, Baretton, Gustavo, Meier, Friedegund, Thiede, Christian, Schmitz, Marc, Platzbecker, Uwe |
| Publisher | American Society of Hematology |
| Source Sets | Hochschulschriftenserver (HSSS) der SLUB Dresden |
| Language | English |
| Detected Language | English |
| Type | info:eu-repo/semantics/publishedVersion, doc-type:article, info:eu-repo/semantics/article, doc-type:Text |
| Rights | info:eu-repo/semantics/openAccess |
| Relation | 2473-9537, 10.1182/bloodadvances.2017014811 |
Page generated in 0.002 seconds